

1 **Resistance to anti-orthopoxviral drug tecovirimat (TPOXX[®]) during the 2022 mpox outbreak in**
2 **the US**

3
4 Todd G. Smith ^{a*}, Crystal M. Gigante ^a, Nhien T. Wynn ^a, Audrey Matheny ^a, Whitney Davidson ^a, Yong
5 Yang ^a, Rene Edgar Condori ^a, Kyle O'Connell ^{b,c}, Lynsey Kovar ^{b,d}, Tracie L. Williams ^e, Yon C. Yu ^f,
6 Brett W. Petersen ^a, Nicolle Baird ^a, David Lowe ^a, Yu Li ^a, Panayampalli S. Satheshkumar ^a, and
7 Christina L. Hutson ^a

8
9 ^a Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National
10 Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton
11 Rd NE, Atlanta GA, 30333, USA

12 ^b Office of Advanced Molecular Detection, National Center for Emerging and Zoonotic Infectious
13 Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta GA, 30333, USA

14 ^c Health Data and AI, Deloitte Consulting LLC, 1919 N. Lynn St, Arlington VA 22209.

15 ^d Leidos Inc., Reston, VA 20190, USA

16 ^e Clinical Chemistry Branch, Division of Laboratory Sciences, National Center for Environmental
17 Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta GA, 30341, USA

18 ^f Emergency Preparedness and Response Branch, Division of Preparedness and Emerging Infections,
19 National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, 1600
20 Clifton Rd NE, Atlanta GA, 30333, USA

21
22 * Corresponding Author

23 Tel: 404-639-2282

24 Fax: 404-639-1564

25 Email: tgsmith1@cdc.gov

26

27 **Abstract**

28 Background: During the 2022 multinational outbreak of monkeypox virus (MPXV) clade IIb, the
29 antiviral drug tecovirimat (TPOXX[®]) was deployed in the US on a large scale for the first time ever. The
30 MPXV F13L gene homolog encodes the target of tecovirimat, and single amino acid changes in the F13
31 protein are known to cause resistance to tecovirimat in orthopoxviruses (OPXV).

32 Methods: Whole genome metagenomic sequencing and amplicon-based sequencing targeting the F13L
33 gene was used to identify nine mutations previously reported to cause resistance in other OPXV along
34 with ten novel mutations that have been identified from the 2022 mpox outbreak. A cytopathic effect
35 assay, previously established at CDC as part of WHO smallpox research, was adapted to MPXV for
36 tecovirimat phenotype testing of virus isolated from mpox patients.

37 Results: As of March 2023, in total, 70 isolates from 40 patients were tested, and 50 of these isolates
38 from 26 patients were found to have a resistant phenotype. Most resistant isolates were associated with
39 severely immunocompromised mpox patients on multiple courses of TPOXX treatment; while isolates
40 with F13 mutations identified by routine surveillance of patients not treated with TPOXX have remained
41 sensitive.

42 Conclusions: These data indicate that tecovirimat resistance is developing in immunocompromised
43 patients treated with TPOXX and that for isolates that we have analyzed, the frequency of resistant
44 viruses remain relatively low (< 1%) compared to the total number of patients treated with TPOXX.

45 These findings inform our understanding of when tecovirimat resistance is likely to occur and highlight
46 the need for additional OPXV therapeutics.

47

48 **Key Words**

49 Antiviral, Tecovirimat, ST-246, TPOXX, monkeypox virus, mpox, orthopoxvirus

50 **Original Research**

51 In May 2022, an outbreak of monkeypox virus (MPXV) clade IIb (formerly West African clade)
52 was first identified in the US¹. Since that time over 32,000 cases and 38 deaths associated with the
53 outbreak have been identified in the US. Cases peaked the first week of August 2022 in the US with 459
54 cases per week. The US has identified more cases than any other country in the global outbreak².

55 The FDA licensed the therapeutic agent TPOXX[®] containing the drug tecovirimat (i.e. ST-246)
56 under the animal rule for smallpox treatment in 2018³. Tecovirimat has been tested extensively in cell
57 culture⁴⁻⁶ and within many orthopoxvirus (OPXV) animal models⁷⁻¹⁵, including the non-human primate
58 variola virus (VARV) model^{16,17}. Although tecovirimat has shown efficacy against multiple OPXV, it
59 has also been noted that nucleotide alterations to the orthopoxviral F13L gene homolog leading to amino
60 acid (AA) substitutions in the F13 protein (also known as VP37) allows for resistance^{4,18}. Additionally,
61 resistance emerged during use of tecovirimat in an extended treatment course of an individual with
62 progressive vaccinia¹⁹.

63 Because TPOXX is only licensed for treatment of smallpox, CDC holds an expanded access
64 investigational new drug protocol for treatment of non-variola OPXV infections, including mpox. Since
65 June 2022, 6929 patients have received TPOXX for mpox treatment in the US. A fraction of these have
66 been severe cases where patients have moderate to severe immunocompromise usually due to
67 uncontrolled HIV infection²⁰. We have received specimens from 432 patients that received TPOXX and
68 resistance was possible or suspected based on clinical data (Fig. 1A). Specimens have been tested from
69 40 patients, and a resistant phenotype has been confirmed in 26 patients (Fig 1B).

70 During the mpox outbreak, whole genome metagenomic sequencing and more recently
71 amplicon-based sequencing targeting the F13L gene have been used to screen for changes in the MPXV
72 F13L homolog (Table S1 including methods). A total of 2,181 CDC-generated sequences have been
73 screened by either passive genomic surveillance (n=2,049) or targeted F13L sequencing (n=132). Only
74 genomic sequencing completed at CDC was included because the raw data were required to find minor

75 variants. The primary outbreak strain (MPXV clade IIB lineage B.1) has a substitution, E353K, in the
76 F13 protein that is not present in the secondary outbreak strain (lineage A.2), historical clade IIB
77 sequences from Nigeria, or MPXV clade IIA²¹. Since the E353K substitution was not previously
78 described in other OPXV, the effect on tecovirimat phenotype was unknown. A cytopathic effect (CPE)
79 assay, used at CDC to test VARV sensitivity to tecovirimat, was adapted to MPXV as described
80 previously²¹. Briefly, MPXV was cultured from clinical specimens which were decoded but not
81 anonymous. A gradient of tecovirimat was applied to confluent cell monolayers, then cells were infected
82 with the isolated MPXV and incubated for 72 hours. Wells were fixed, stained, and absorbance at 570
83 nm was measured. The CPE assay was used to show that MPXV isolates with the E353K mutation
84 remained sensitive to tecovirimat^{21,22}.

85 In total, 86 samples from 55 patients produced sequences with AA changes (other than E353K) in
86 the F13 protein relative to MPXV Clade IIB variant B.1 reference ON563414 (Table 1). Isolates with
87 AA substitutions D100N, D217N, D248N and D256N, identified by routine sequencing of samples from
88 patients not treated with TPOXX, have remained sensitive (Table 1). Nine AA mutations, A290V,
89 A295E, D294V, H238Q, I372N, L297ins, N267D, N267del, and A288P, that were previously identified
90 in other OPXV^{18,19,23}, were confirmed resistant by phenotypic testing (Table 1). One confirmed
91 resistance mutation, T289A, had not been described before the 2022 mpox outbreak²⁴. T289A resulted
92 in up to an 8-fold increase in the half-maximal effective concentration (EC₅₀) when compared to the
93 MPXV clade IIA reference strain (US, 2003). This position is part of the predicted tecovirimat binding
94 site and adjacent to A288P and A290V which both confer resistance¹⁸. Five other AA substitutions
95 (K174N, S215F, P243S, Y285H, R291K) were identified but the effect of these mutations has not yet
96 been determined^{24,25}. These mutations have only been observed and tested in combination with other
97 known resistance mutations.

98 For phenotype testing, an isolate was considered resistant if the increase in the EC₅₀ compared to
99 the MPXV clade IIA (US, 2003) reference strain was ≥ 2 -fold. Isolates with 2- to 9-fold change were

100 considered partially resistant and isolates with ≥ 10 -fold change were considered resistant²⁴. Forty-three
101 isolates from 22 patients were resistant, and seven isolates from five patients were partially resistant.
102 One patient with partially resistant isolates also had at least one other isolate that was resistant. The
103 clinical relevance of partially resistant and/or resistant isolates remains unknown.

104 Multiple lines of evidence point to tecovirimat resistance developing during drug treatment in
105 most patients. First, genome sequencing has revealed unique mutational profiles from different sample
106 sites from the same patient (Fig. 2.A). Indicating different viral subpopulations were selected at different
107 sites during treatment. Second, longitudinal sampling was investigated for four of the 26 patients with a
108 resistant isolate and showed samples before tecovirimat treatment were sensitive whereas later samples
109 were resistant (Fig. 2.B). An exception was found for one patient. T289A was detected in 58% of reads,
110 with minor populations of A295E (9%) and N267del (22%), from a sample the day before the patient
111 started tecovirimat treatment. A second sample from the same patient after tecovirimat treatment showed
112 the T289A mutation alone was selected (93%). Additionally, N267del was detected in a cluster of cases
113 with no known TPOXX treatment by Los Angeles County Department of Public Health (manuscript in
114 preparation). Whether these drug-resistant cases were acquired from another person treated with
115 tecovirimat is unknown but is a viable hypothesis. These rare cases show that viruses with mutations in
116 F13L resulting in tecovirimat resistance can be transmitted from person to person.

117 For patients that had at least one specimen with confirmed tecovirimat resistance, all 26 had HIV
118 infection. Of the 26 patients, 17 had a CD4⁺ T-cell count available, all 17 were below 350 cell/mm³, and
119 15 were below 200 cell/mm³. Five of the 26 patients died^{24,25}. All five deceased patients had CD4⁺ T-
120 cell counts below 200 cell/mm³. At least 23 of 26 patients were hospitalized. No medical history was
121 available for one patient, and the medical history concerning hospitalization was not clear for the
122 remaining two patients. All 26 patients received tecovirimat. Exact data on length of tecovirimat
123 exposure is difficult to obtain because of possible noncompliance with oral administration and multiple
124 rounds of treatment where drug administration stops and starts. We estimated the average length of

125 tecovirimat treatment using the reported start date of TPOXX treatments. Dates were available for 21 of
126 the 26 patients, and the average length of tecovirimat treatment was 32 days with a range of 14 to 77
127 days (standard regimen is 14 days).

128 Our report has several limitations. The phenotype assay is culture-based making it labor
129 intensive and low throughput. As of March 2023, we have phenotyped 70 specimens from 40 patients.
130 The lag in testing means most of the specimens that have been tested are from September to November
131 2022, so results only give a retrospective sample of possible drug resistance. Submission of samples for
132 tecovirimat sensitivity is voluntary (but encouraged for suspected tecovirimat resistance), so sampling
133 bias may exist for certain physicians, hospitals, or states and may make it appear that certain states have
134 more drug-resistance than others (Fig. 1). As genomic sequencing has increased, we have prioritized
135 samples with predicted resistance mutations for phenotype testing. Mixed populations of cultured virus
136 were tested due to the efficiency needed for a public health emergency. In the future, we will begin
137 plaque purification for selected samples to test clonal populations.

138 Finally, these results confirm that tecovirimat resistance mutations are being selected in human
139 mpox patients by tecovirimat treatment. Resistance has been confirmed in a small percentage of cases
140 for which specimens have been sent to CDC, currently < 1% with the potential to be ~5% as testing
141 continues. Characteristics of patients with resistant isolates are very similar: HIV infection with very low
142 CD4⁺ T-cell counts and potential for extensive tecovirimat exposure while hospitalized. In very rare
143 cases, a drug-resistant virus appears to have been transmitted to another person. Genomic and phenotype
144 testing are ongoing. These results may be useful when considering treatment for patients that match the
145 clinical profile described within, and that aggressive early dosing/combination therapy regimens could
146 be considered in those instances²⁰. Results will also provide critical knowledge to potentially build a
147 genomic assay for early detection of resistance mutations which could be used to inform clinical care
148 decisions. This report describes the largest number of tecovirimat resistant isolates from humans
149 reported to date and provides crucial data on the AA changes leading to resistance in MPXV paired with

150 clinical outcomes. These combined data may inform decisions on tecovirimat utilization in the future.
151 These findings also highlight the need for additional, well-tolerated OPXV therapeutics with different
152 modes of action, particularly for use with immunocompromised patients.

153 For clinicians concerned about tecovirimat resistance, we encourage enrolling patients in the
154 CDC VIRISMAP study (cdc.gov/poxvirus/mpox/clinicians/treatment.html) and the STOMP trial
155 (stomptpoxx.org).

156

157 **Ethics Statement**

158 The activities in this report were reviewed by the Human Subjects Advisor in the National Center for
159 Emerging and Zoonotic Diseases at the Centers for Disease Control and Prevention and determined that
160 it does not meet the regulatory definition of research under provision 45 CFR 46.102(l); the activities
161 fall under public health surveillance and do not require IRB review.

162 **Disclaimer**

163 Use of trade names and commercial sources are for identification only and do not imply endorsement by
164 the U.S. Department of Health and Human Services. The findings and conclusions in this report are
165 those of the authors and do not necessarily represent the views of the Centers for Disease Control and
166 Prevention or their institutions.

167 **Acknowledgements**

168 This study did not receive any external funding. We thank Hui Zhao and members of CDC Division of
169 Scientific Resources Genome Sequencing Lab, CDC Advanced Molecular Detection Biotechnology
170 Core Facility Branch, and CDC Mpox Response Bioinformatics Unit for support with genome
171 sequencing. We thank Yoshinori Nakazawa for technical assistance. We thank all clinicians, hospitals,
172 state and local public health laboratories (PHLs) that have submitted mpox specimens to CDC. We
173 thank the following partners that have specifically submitted mpox specimens for tecovirimat resistance
174 testing at the time of this report: California - Los Angeles County Public Health Laboratory; California

175 Department of Public Health, Microbial Diseases Laboratory; California Department of Public Health,
176 Viral and Rickettsial Disease Laboratory; Florida Bureau of Public Health Laboratories - Jacksonville;
177 Florida Bureau of Public Health Laboratories - Miami; Florida Bureau of Public Health Laboratories -
178 Tampa; Georgia Department of Public Health Laboratory; Illinois Department of Public Health, Chicago
179 Laboratory; Indiana State Department of Health Laboratory Services; Louisiana Office of Public Health
180 Laboratories; Maryland Department of Health, Laboratories Administration; North Carolina State
181 Laboratory of Public Health; Nevada State Public Health Laboratory; New York City Department of
182 Health and Mental Hygiene; Ohio Department of Health Laboratory; Pennsylvania Department of
183 Health, Bureau of Laboratories; Rhode Island State Health Laboratories; Tennessee Division of
184 Laboratory Services; Texas Department of State Health Services, Lab Services Section; Texas-Houston
185 Health Department Laboratory; Virginia Division of Consolidated Laboratory Services.

186

187 **References**

- 188 1. Minhaj FS, Ogale YP, Whitehill F, et al. Monkeypox Outbreak - Nine States, May 2022.
189 MMWR Morb Mortal Wkly Rep 2022;71(23):764-769. DOI: 10.15585/mmwr.mm7123e1.
- 190 2. Centers for Disease Control and Prevention. 2022 Mpox Outbreak Global Map. 29Mar2023
191 (<https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html>).
- 192 3. Merchlinsky M, Albright A, Olson V, et al. The development and approval of tecoviromat
193 (TPOXX®), the first antiviral against smallpox. Antiviral Res 2019;168:168-174.
- 194 4. Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246)
195 inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol
196 2005;79(20):13139-49. DOI: 10.1128/JVI.79.20.13139-13149.2005.
- 197 5. Smith SK, Olson VA, Karem KL, Jordan R, Hrubby DE, Damon IK. In vitro efficacy of ST246
198 against smallpox and monkeypox. Antimicrob Agents Chemother 2009;53(3):1007-12. DOI:
199 10.1128/AAC.01044-08.

- 200 6. Duraffour S, Snoeck R, de Vos R, et al. Activity of the anti-orthopoxvirus compound ST-246
201 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. *Antivir*
202 *Ther* 2007;12(8):1205-16. (<https://www.ncbi.nlm.nih.gov/pubmed/18240860>).
- 203 7. Berhanu A, King DS, Mosier S, et al. ST-246 inhibits in vivo poxvirus dissemination, virus
204 shedding, and systemic disease manifestation. *Antimicrob Agents Chemother* 2009;53(12):4999-5009.
205 DOI: 10.1128/AAC.00678-09.
- 206 8. Grosenbach DW, Berhanu A, King DS, et al. Efficacy of ST-246 versus lethal poxvirus
207 challenge in immunodeficient mice. *Proc Natl Acad Sci U S A* 2010;107(2):838-43. DOI:
208 10.1073/pnas.0912134107.
- 209 9. Jordan R, Goff A, Frimm A, et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox
210 model: determination of the minimal effective dose and human dose justification. *Antimicrob Agents*
211 *Chemother* 2009;53(5):1817-22. DOI: 10.1128/AAC.01596-08.
- 212 10. Zaitseva M, Shotwell E, Scott J, et al. Effects of postchallenge administration of ST-246 on
213 dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted
214 with T cells. *J Virol* 2013;87(10):5564-76. DOI: 10.1128/JVI.03426-12.
- 215 11. Smith SK, Self J, Weiss S, et al. Effective antiviral treatment of systemic orthopoxvirus disease:
216 ST-246 treatment of prairie dogs infected with monkeypox virus. *J Virol* 2011;85(17):9176-87. DOI:
217 10.1128/JVI.02173-10.
- 218 12. Sbrana E, Jordan R, Hruby DE, et al. Efficacy of the antipoxvirus compound ST-246 for
219 treatment of severe orthopoxvirus infection. *Am J Trop Med Hyg* 2007;76(4):768-73.
220 (<https://www.ncbi.nlm.nih.gov/pubmed/17426185>).
- 221 13. Santos-Fernandes E, Beltrame CO, Byrd CM, et al. Increased susceptibility of Cantagalo virus to
222 the antiviral effect of ST-246(R). *Antiviral Res* 2013;97(3):301-11. DOI:
223 10.1016/j.antiviral.2012.11.010.

- 224 14. Quenelle DC, Buller RM, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally
225 against systemic orthopoxvirus infections in mice. *Antimicrob Agents Chemother* 2007;51(2):689-95.
226 DOI: 10.1128/AAC.00879-06.
- 227 15. Nalca A, Hatkin JM, Garza NL, et al. Evaluation of orally delivered ST-246 as postexposure
228 prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. *Antiviral Res*
229 2008;79(2):121-7. DOI: 10.1016/j.antiviral.2008.03.005.
- 230 16. Mucker EM, Goff AJ, Shamblin JD, et al. Efficacy of tecovirimat (ST-246) in nonhuman
231 primates infected with variola virus (Smallpox). *Antimicrob Agents Chemother* 2013;57(12):6246-53.
232 DOI: 10.1128/AAC.00977-13.
- 233 17. Huggins J, Goff A, Hensley L, et al. Nonhuman primates are protected from smallpox virus or
234 monkeypox virus challenges by the antiviral drug ST-246. *Antimicrob Agents Chemother*
235 2009;53(6):2620-5. DOI: 10.1128/AAC.00021-09.
- 236 18. Duraffour S, Lorenzo MM, Zoller G, et al. ST-246 is a key antiviral to inhibit the viral F13L
237 phospholipase, one of the essential proteins for orthopoxvirus wrapping. *J Antimicrob Chemother*
238 2015;70(5):1367-80. DOI: 10.1093/jac/dku545.
- 239 19. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case description and
240 laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. *J Infect Dis*
241 2012;206(9):1372-85. DOI: 10.1093/infdis/jis510.
- 242 20. Rao AK, Schrodtt CA, Minhaj FS, et al. Interim Clinical Treatment Considerations for Severe
243 Manifestations of Mpox - United States, February 2023. *MMWR Morb Mortal Wkly Rep*
244 2023;72(9):232-243. DOI: 10.15585/mmwr.mm7209a4.
- 245 21. Gigante CM, Korber B, Seabolt MH, et al. Multiple lineages of monkeypox virus detected in the
246 United States, 2021-2022. *Science* 2022;378(6619):560-565. DOI: 10.1126/science.add4153.
- 247 22. Bojkova D, Bechtel M, Rothenburger T, et al. Drug Sensitivity of Currently Circulating Mpox
248 Viruses. *N Engl J Med* 2023;388(3):279-281. DOI: 10.1056/NEJMc2212136.

- 249 23. Food and Drug Administration. FDA Mpox Response: TPOXX (tecovirimat): Information for
250 the Scientific Community: Table: Orthopoxvirus VP37 Amino Acid Substitutions Associated with
251 Tecovirimat Resistance. 30Mar2023 ([https://www.fda.gov/emergency-preparedness-and-response/mcm-
252 issues/fda-mpox-response](https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/fda-mpox-response)).
- 253 24. Garrigues JM, Hemarajata P, Karan A, et al. Identification of tecovirimat resistance-associated
254 mutations in human monkeypox virus - Los Angeles County, September 2022 – January 2023. in press
255 2023.
- 256 25. Alarcon J, Kim M, Terashita D, et al. An Mpox-Related Death in the United States. *N Engl J*
257 *Med* 2023;388(13):1246-1247. DOI: 10.1056/NEJMc2214921.
- 258

259 Table 1. F13 mutations identified in patients (n=???) treated with TPOXX


| AA Substitution ^a | Isolates | Patients | EC ₅₀ (μM) | Fold Change ^b |
|-------------------------------------|----------|----------|-----------------------|--------------------------|
| A288P | 5 | 3 | 0.5 to >500 | 29 to >29000 |
| A288P, I372N | 1 | 1 | >150 | >8600 |
| A288P, A290V, D294V | 3 | 1 | 0.66 to >500 | 38 to >29000 |
| A288P, A290V, L297ins | 1 | 1 | >500 | >29000 |
| A288P, A290V, I372N | 1 | 1 | 15 | 880 |
| A288P, D294V, A295E | 1 | 1 | 1.4 | 83 |
| A290V | 8 | 8 | 0.17 to 43 | 10 to 2500 |
| A290V, I372N | 3 | 3 | 30 to 32 | 1700 to 1800 |
| A295E | 2 | 2 | 2.0 to 3.3 | 110 to 190 |
| D100N | 2 | 2 | 0.008 | -2 |
| D217N | 7 | 7 | 0.007 to 0.012 | -2.4 to -1.3 |
| D248N | 1 | 1 | not tested | |
| D256N | 3 | 3 | 0.009 | -1.8 |
| D294V | 6 | 6 | 0.34 to 1.4 | 19 to 78 |
| D294V, A295E | 1 | 1 | 1.5 | 86 |
| H238Q | 3 | 3 | 0.54 to 0.6 | 28 to 34 |
| H238Q, A288P, D294V, I372N | 1 | 1 | ~5.2 | ~290 |
| H238Q, N267D, A295E | 1 | 1 | 24 | 1400 |
| I372N | 10 | 8 | 0.04 to 77 | 2.3 to 4400 |
| K174N, N267D | 1 | 1 | 12 | 720 |
| N267D | 2 | 2 | 11 | 630 |
| N267D, A288P | 3 | 3 | 16 | 900 |
| N267D, A290V | 1 | 1 | 2.0 | 110 |
| N267D, D294V | 1 | 1 | 12 | 680 |
| N267D, A288P, A290V, D294V | 1 | 1 | >500 | >29000 |
| N267D, A288P, A290V, A295E, L297ins | 1 | 1 | >500 | >29000 |
| N267D, A288P, A290V, A295E, I372N | 1 | 1 | >500 | >29000 |
| N267D, A288P, A290V, D294V, I372N | 1 | 1 | >500 | >29000 |
| N267del | 2 | 2 | 3.0 | 170 |
| N267del, N267D | 1 | 1 | not tested | |
| N267del, N267D, A295E | 2 | 2 | 2.9 to 18 | 160 to 1000 |
| N267del, N267D, A288P, A295E | 1 | 1 | not tested | |
| N267del, N267D, D294V, A295E | 1 | 1 | 2.5 | 140 |
| N267del, A288P, A295E | 1 | 1 | >500 | >29000 |
| N267del, T289A, A295E | 1 | 1 | 0.26 | 15 |
| N267del, A290V, I372N | 1 | 1 | not tested | |
| P243S, A288P, A290V | 1 | 1 | 0.56 | 32 |
| S215F, T289A, A290V, I372N | 1 | 1 | not tested | |
| T245I, A290V | 1 | 1 | 0.17 | 10 |
| T289A | 2 | 2 | 0.078 to 0.14 | 3.7 to 8.0 |
| T289A, R291K | 1 | 1 | 1.7 | 98 |
| T289A, I372N | 1 | 1 | not tested | |
| Y285H, I372N | 1 | 1 | not tested | |
| Total with genomic changes | 86 | 55 | | |
| Total with resistant phenotype | 50 | 26 | | |

261 ^a All specimens belong to MPXV clade IIb lineage B.1 and contain E353K substitution in addition to the
262 listed substitutions. All substitutions detected from a specimen are listed regardless of their proportion in
263 the viral population. Insertions (ins) and deletions (del) were detected in addition to substitutions.

264 ^b Fold change was calculated based on the EC₅₀ of the reference strain MPXV clade IIa (US, 2003)
265 which was 0.0175 μM.


266 Figure 1. Surveillance for tecovirimat resistance in the US as of March, 2023

267 A.



268


269 B.



270


271 Figure 2. Examples of tecovirimat resistance

272 A.



273

274 B.



275

276 Patient samples were sequenced, cultured, and subjected to tecovirimat sensitivity testing in a cytopathic
277 effect assay. (A) Different samples from the same patient showed different F13 AA substitutions which
278 result in different levels of resistance compared to the wild-type (Wt) control (MPXV clade IIa, US,
279 2003). (B) Samples from the same patient at different times before and after starting tecovirimat
280 treatment in Aug 2022 showing sensitivity before drug treatment and increasing resistance after drug
281 treatment.